Cargando…

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders

Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer’s disease (AD). The use of fully automated biomarker assays has been shown to reduce the intra- and inter-laboratory variability, which is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellomo, Giovanni, Indaco, Antonio, Chiasserini, Davide, Maderna, Emanuela, Paolini Paoletti, Federico, Gaetani, Lorenzo, Paciotti, Silvia, Petricciuolo, Maya, Tagliavini, Fabrizio, Giaccone, Giorgio, Parnetti, Lucilla, Di Fede, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044304/
https://www.ncbi.nlm.nih.gov/pubmed/33867925
http://dx.doi.org/10.3389/fnins.2021.647783
_version_ 1783678455473242112
author Bellomo, Giovanni
Indaco, Antonio
Chiasserini, Davide
Maderna, Emanuela
Paolini Paoletti, Federico
Gaetani, Lorenzo
Paciotti, Silvia
Petricciuolo, Maya
Tagliavini, Fabrizio
Giaccone, Giorgio
Parnetti, Lucilla
Di Fede, Giuseppe
author_facet Bellomo, Giovanni
Indaco, Antonio
Chiasserini, Davide
Maderna, Emanuela
Paolini Paoletti, Federico
Gaetani, Lorenzo
Paciotti, Silvia
Petricciuolo, Maya
Tagliavini, Fabrizio
Giaccone, Giorgio
Parnetti, Lucilla
Di Fede, Giuseppe
author_sort Bellomo, Giovanni
collection PubMed
description Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer’s disease (AD). The use of fully automated biomarker assays has been shown to reduce the intra- and inter-laboratory variability, which is a critical factor when defining cut-off values. The calculation of cut-off values is often influenced by the composition of AD and control groups. Indeed, the clinically defined AD group may include patients affected by other forms of dementia, while the control group is often very heterogeneous due to the inclusion of subjects diagnosed with other neurological diseases (OND). In this context, unsupervised machine learning approaches may overcome these issues providing unbiased cut-off values and data-driven patient stratification according to the sole distribution of biomarkers. In this work, we took advantage of the reproducibility of automated determination of the CSF core AD biomarkers to compare two large cohorts of patients diagnosed with different neurological disorders and enrolled in two centers with established expertise in AD biomarkers. We applied an unsupervised Gaussian mixture model clustering algorithm and found that our large series of patients could be classified in six clusters according to their CSF biomarker profile, some presenting a typical AD-like profile and some a non-AD profile. By considering the frequencies of clinically defined OND and AD subjects in clusters, we subsequently computed cluster-based cut-off values for Aβ42/Aβ40, p-tau, and t-tau. This approach promises to be useful for large-scale biomarker studies aimed at providing efficient biochemical phenotyping of neurological diseases.
format Online
Article
Text
id pubmed-8044304
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80443042021-04-15 Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders Bellomo, Giovanni Indaco, Antonio Chiasserini, Davide Maderna, Emanuela Paolini Paoletti, Federico Gaetani, Lorenzo Paciotti, Silvia Petricciuolo, Maya Tagliavini, Fabrizio Giaccone, Giorgio Parnetti, Lucilla Di Fede, Giuseppe Front Neurosci Neuroscience Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer’s disease (AD). The use of fully automated biomarker assays has been shown to reduce the intra- and inter-laboratory variability, which is a critical factor when defining cut-off values. The calculation of cut-off values is often influenced by the composition of AD and control groups. Indeed, the clinically defined AD group may include patients affected by other forms of dementia, while the control group is often very heterogeneous due to the inclusion of subjects diagnosed with other neurological diseases (OND). In this context, unsupervised machine learning approaches may overcome these issues providing unbiased cut-off values and data-driven patient stratification according to the sole distribution of biomarkers. In this work, we took advantage of the reproducibility of automated determination of the CSF core AD biomarkers to compare two large cohorts of patients diagnosed with different neurological disorders and enrolled in two centers with established expertise in AD biomarkers. We applied an unsupervised Gaussian mixture model clustering algorithm and found that our large series of patients could be classified in six clusters according to their CSF biomarker profile, some presenting a typical AD-like profile and some a non-AD profile. By considering the frequencies of clinically defined OND and AD subjects in clusters, we subsequently computed cluster-based cut-off values for Aβ42/Aβ40, p-tau, and t-tau. This approach promises to be useful for large-scale biomarker studies aimed at providing efficient biochemical phenotyping of neurological diseases. Frontiers Media S.A. 2021-03-31 /pmc/articles/PMC8044304/ /pubmed/33867925 http://dx.doi.org/10.3389/fnins.2021.647783 Text en Copyright © 2021 Bellomo, Indaco, Chiasserini, Maderna, Paolini Paoletti, Gaetani, Paciotti, Petricciuolo, Tagliavini, Giaccone, Parnetti and Di Fede. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Bellomo, Giovanni
Indaco, Antonio
Chiasserini, Davide
Maderna, Emanuela
Paolini Paoletti, Federico
Gaetani, Lorenzo
Paciotti, Silvia
Petricciuolo, Maya
Tagliavini, Fabrizio
Giaccone, Giorgio
Parnetti, Lucilla
Di Fede, Giuseppe
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
title Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
title_full Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
title_fullStr Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
title_full_unstemmed Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
title_short Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
title_sort machine learning driven profiling of cerebrospinal fluid core biomarkers in alzheimer’s disease and other neurological disorders
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044304/
https://www.ncbi.nlm.nih.gov/pubmed/33867925
http://dx.doi.org/10.3389/fnins.2021.647783
work_keys_str_mv AT bellomogiovanni machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT indacoantonio machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT chiasserinidavide machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT madernaemanuela machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT paolinipaolettifederico machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT gaetanilorenzo machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT paciottisilvia machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT petricciuolomaya machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT tagliavinifabrizio machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT giacconegiorgio machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT parnettilucilla machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders
AT difedegiuseppe machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders